99 related articles for article (PubMed ID: 14579030)
1. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
Perniok A; Rubbert-Roth A
Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
[TBL] [Abstract][Full Text] [Related]
2. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
3. [Blockade of TNFalpha--new therapeutic principle in severe rheumatoid arthritis].
Larsson P; Bratt J; Harju A; van Vollenhoven R; Klareskog L
Lakartidningen; 2001 Feb; 98(8):828-31. PubMed ID: 11265568
[TBL] [Abstract][Full Text] [Related]
4. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
Manger B;
Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
[No Abstract] [Full Text] [Related]
5. The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis.
Cohen SB
Rheum Dis Clin North Am; 2004 May; 30(2):365-80, vii. PubMed ID: 15172046
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapeutics for rheumatoid arthritis.
Bingham CO
Bull NYU Hosp Jt Dis; 2008; 66(3):210-5. PubMed ID: 18937634
[TBL] [Abstract][Full Text] [Related]
7. Investigational agents for rheumatoid arthritis.
Merkel PA; Letourneau EN; Polisson RP
Rheum Dis Clin North Am; 1995 Aug; 21(3):779-96. PubMed ID: 8619099
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
[TBL] [Abstract][Full Text] [Related]
9. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
[TBL] [Abstract][Full Text] [Related]
10. TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis.
Rubbert-Roth A
Curr Opin Mol Ther; 2010 Feb; 12(1):115-23. PubMed ID: 20140823
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
[No Abstract] [Full Text] [Related]
12. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of rheumatoid arthritis with cytokine antagonists].
Manger B
Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):101-4. PubMed ID: 10355058
[TBL] [Abstract][Full Text] [Related]
14. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
Ferraccioli G; Gremese E
Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
[TBL] [Abstract][Full Text] [Related]
15. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
Jit M; Henderson B; Stevens M; Seymour RM
Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
[TBL] [Abstract][Full Text] [Related]
16. [Medical treatment of juvenile idiopathic arthritis].
Horneff G; Augustin S
Med Monatsschr Pharm; 2008 Sep; 31(9):326-36; quiz 337-8. PubMed ID: 18831464
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of rheumatoid arthritis: targeting cytokines.
Zwerina J; Redlich K; Schett G; Smolen JS
Ann N Y Acad Sci; 2005 Jun; 1051():716-29. PubMed ID: 16127012
[TBL] [Abstract][Full Text] [Related]
18. Biological therapies for rheumatoid arthritis: progress to date.
Malviya G; Salemi S; Laganà B; Diamanti AP; D'Amelio R; Signore A
BioDrugs; 2013 Aug; 27(4):329-45. PubMed ID: 23558378
[TBL] [Abstract][Full Text] [Related]
19. [Basic therapeutic and immunosuppressive drugs in rheumatoid arthritis. No fear of "heavy weapons"].
Krüger K
MMW Fortschr Med; 2002 Aug; 144(33-34):25-30. PubMed ID: 12380140
[No Abstract] [Full Text] [Related]
20. Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases.
Siebert S; Tsoukas A; Robertson J; McInnes I
Pharmacol Rev; 2015; 67(2):280-309. PubMed ID: 25697599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
